- Home
- HRMY vs RXO Comparison
HRMY vs RXO Comparison
Compare HRMY & RXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRMY | RXO |
|---|---|---|
| Founded | 2017 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | HRMY | RXO |
|---|---|---|
| Price | $36.78 | $15.84 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 15 |
| Target Price | ★ $49.75 | $15.77 |
| AVG Volume (30 Days) | 615.1K | ★ 2.1M |
| Earning Date | 02-24-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.44 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | $825,944,000.00 | ★ $5,940,000,000.00 |
| Revenue This Year | $23.29 | $27.80 |
| Revenue Next Year | $15.98 | $2.87 |
| P/E Ratio | $11.58 | ★ N/A |
| Revenue Growth | 21.13 | ★ 53.85 |
| 52 Week Low | $25.52 | $10.43 |
| 52 Week High | $40.93 | $26.92 |
Technical Indicators
Market Signals| Indicator | HRMY | RXO |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 63.76 |
| Support Level | $35.16 | $14.35 |
| Resistance Level | $37.08 | $15.67 |
| Average True Range (ATR) | 1.43 | 0.78 |
| MACD | -0.21 | 0.17 |
| Stochastic Oscillator | 43.22 | 92.26 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About RXO RXO Inc.
RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.